The Experimental Therapeutics Core serves as the focal point for identifying lead compounds through targeted high throughput screens, analysis of structure-function relationships to identify targets for enhancing activity, synthesizing active derivatives, and performing in vitro screening of derivatized compounds. The ET Core also provide capabilities in scaled production via collaborations. These capabilities are intended to facilitate development of new therapeutics and improve pre-clinical drug evaluation for investigators peripherally involved in Experimental Therapeutics development. Specific services are in silico molecular modeling, screening of defined commercially available compound libraries, derivatization of lead molecules, and chemical analysis of newly synthesized compounds.

In silico drug design magnification


  • JMS-S3000 SpiralTOF MALDI-TOF Mass Spectrometer
  • JEOL 400 MHz NMR Spectrometer
  • Hudson Robotics SOLO Auto Pipettor
  • Lyovapor L-300 Freeze Dryer



Mark McLaughlin, PhD | mark.mclaughlin@hsc.wvu.edu | (304) 293-1450


Please remember to acknowledge support for the Experimental Therapeutics Core in all your publications:

Compounds were synthesized and characterized in the West Virginia University Experimental Therapeutics Core which has been supported by the WVU HSC Office of Research and Graduate Education and NIH grants P20GM103434 and U54GM104942.

Research Forrest